{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T15:17:12Z","timestamp":1772464632753,"version":"3.50.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,12,27]],"date-time":"2019-12-27T00:00:00Z","timestamp":1577404800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2019,12,27]],"date-time":"2019-12-27T00:00:00Z","timestamp":1577404800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Sumitomo Dainippon Pharma Co., Ltd."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1007\/s40263-019-00692-6","type":"journal-article","created":{"date-parts":[[2019,12,27]],"date-time":"2019-12-27T15:02:41Z","timestamp":1577458961000},"page":"103-116","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Long-Term Safety and Efficacy of Blonanserin Transdermal Patches in Japanese Patients with Schizophrenia: A 52-Week Open-Label, Multicenter Study"],"prefix":"10.1007","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3189-6076","authenticated-orcid":false,"given":"Nakao","family":"Iwata","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0547-2843","authenticated-orcid":false,"given":"Jun","family":"Ishigooka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6274-9584","authenticated-orcid":false,"given":"Ichiro","family":"Naoi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8086-2281","authenticated-orcid":false,"given":"Masahiro","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2867-1810","authenticated-orcid":false,"given":"Yuichi","family":"Kanamori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7699-9840","authenticated-orcid":false,"given":"Hiroshi","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6074-0068","authenticated-orcid":false,"given":"Teruhiko","family":"Higuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,12,27]]},"reference":[{"issue":"1","key":"692_CR1","doi-asserted-by":"publisher","first-page":"65","DOI":"10.2165\/11202620-000000000-00000","volume":"24","author":"ED Deeks","year":"2010","unstructured":"Deeks ED, Keating GM. Blonanserin: a review of its use in the management of schizophrenia. CNS Drugs. 2010;24(1):65\u201384.","journal-title":"CNS Drugs"},{"key":"692_CR2","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.jpsychires.2015.07.015","volume":"69","author":"H Li","year":"2015","unstructured":"Li H, Yao C, Shi J, Yang F, Qi S, Wang L, et al. Comparative study of the efficacy and safety between blonanserin and risperidone for the treatment of schizophrenia in Chinese patients: a double-blind, parallel-group multicenter randomized trial. J Psychiatr Res. 2015;69:102\u20139.","journal-title":"J Psychiatr Res"},{"key":"692_CR3","unstructured":"Sumitomo Dainippon Pharma Co. Ltd. Lonasen tape 20\u00a0mg, 30\u00a0mg, and 40\u00a0mg [Japanese prescribing information]. 2019. http:\/\/www.info.pmda.go.jp\/go\/pack\/11797A0S1025_1_03\/. Accessed August 26, 2019."},{"issue":"11","key":"692_CR4","first-page":"2059","volume":"10","author":"M Murasaki","year":"2007","unstructured":"Murasaki M. Clinical evaluation of blonanserin for schizophrenia: a randomized controlled study comparing blonanserin with haloperidol. Jpn J Clin Psychopharmacol. 2007;10(11):2059\u201379.","journal-title":"Jpn J Clin Psychopharmacol."},{"issue":"12","key":"692_CR5","first-page":"2241","volume":"10","author":"M Murasaki","year":"2007","unstructured":"Murasaki M. Long-term clinical study of blonanserin for schizophrenia: a multicenter open study to determine safety and effectiveness in schizophrenic patients (Kanagawa Region Clinical Psychopharmacology Study Group). Jpn J Clin Psychopharmacol. 2007;10(12):2241\u201357.","journal-title":"Jpn J Clin Psychopharmacol."},{"issue":"2","key":"692_CR6","first-page":"297","volume":"11","author":"S Miura","year":"2008","unstructured":"Miura S. Clinical evaluation of blonanserin for schizophrenia: a randomized controlled study comparing blonanserin with risperidone. Jpn J Clin Psychopharmacol. 2008;11(2):297\u2013314.","journal-title":"Jpn J Clin Psychopharmacol."},{"issue":"1","key":"692_CR7","first-page":"135","volume":"11","author":"T Kinoshita","year":"2008","unstructured":"Kinoshita T. Long-term clinical study of blonanserin for schizophrenia: a multicenter open study to determine safety and effectiveness in schizophrenic patients (Japan-wide study). Jpn J Clin Psychopharmacol. 2008;11(1):135\u201353.","journal-title":"Jpn J Clin Psychopharmacol."},{"issue":"7","key":"692_CR8","doi-asserted-by":"publisher","first-page":"615","DOI":"10.2165\/00023210-200923070-00006","volume":"23","author":"E Garcia","year":"2009","unstructured":"Garcia E, Robert M, Peris F, Nakamura H, Sato N, Terazawa Y. The efficacy and safety of blonanserin compared with haloperidol in acute-phase schizophrenia: a randomized, double-blind, placebo-controlled, multicentre study. CNS Drugs. 2009;23(7):615\u201325.","journal-title":"CNS Drugs"},{"issue":"4","key":"692_CR9","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1097\/WNF.0b013e3181dcda50","volume":"33","author":"J Yang","year":"2010","unstructured":"Yang J, Bahk WM, Cho HS, Jeon YW, Jon DI, Jung HY, et al. Efficacy and tolerability of Blonanserin in the patients with schizophrenia: a randomized, double-blind, risperidone-compared trial. Clin Neuropharmacol. 2010;33(4):169\u201375.","journal-title":"Clin Neuropharmacol"},{"issue":"2","key":"692_CR10","first-page":"52","volume":"52","author":"T Kishi","year":"2018","unstructured":"Kishi T, Matsui Y, Matsuda Y, Katsuki A, Hori H, Yanagimoto H, et al. Efficacy, tolerability, and safety of blonanserin in schizophrenia: an updated and extended systematic review and meta-analysis of randomized controlled trials. Pharmacopsychiatry. 2018;52(2):52\u201362.","journal-title":"Pharmacopsychiatry"},{"issue":"5","key":"692_CR11","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1002\/hup.2487","volume":"30","author":"Cuevas C De Las","year":"2015","unstructured":"De Las Cuevas C, Penate W. Explaining pharmacophobia and pharmacophilia in psychiatric patients: relationship with treatment adherence. Hum Psychopharmacol. 2015;30(5):377\u201383.","journal-title":"Hum Psychopharmacol"},{"issue":"3","key":"692_CR12","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s10865-007-9147-y","volume":"31","author":"KS Ingersoll","year":"2008","unstructured":"Ingersoll KS, Cohen J. The impact of medication regimen factors on adherence to chronic treatment: a review of literature. J Behav Med. 2008;31(3):213\u201324.","journal-title":"J Behav Med"},{"key":"692_CR13","doi-asserted-by":"crossref","unstructured":"Iwata N, Ishigooka J, Kim W-H, Yoon B-H, Lin S-K, Sulaiman AH, et al. Efficacy and safety of blonanserin transdermal patch in patients with schizophrenia: a 6-week randomized, double-blind, placebo-controlled, multicenter study. Schizophr Res. 2019 (ePublished).","DOI":"10.1016\/j.schres.2019.07.055"},{"issue":"6","key":"692_CR14","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1177\/2045125312458311","volume":"2","author":"M Isaac","year":"2012","unstructured":"Isaac M, Holvey C. Transdermal patches: the emerging mode of drug delivery system in psychiatry. Ther Adv Psychopharmacol. 2012;2(6):255\u201363.","journal-title":"Ther Adv Psychopharmacol"},{"key":"692_CR15","unstructured":"Pharmaceuticals and Medical Devices Agency. New drug application review report for Lonasen tape 20\u00a0mg, 30\u00a0mg and 40\u00a0mg. CTD 2.5 Clinical Overview. 2019. http:\/\/www.pmda.go.jp\/drugs\/2019\/P20190704001\/index.html. Accessed 01 Nov 2019."},{"issue":"5","key":"692_CR16","first-page":"301","volume":"80","author":"T Kawamura","year":"1970","unstructured":"Kawamura T, Sasagawa S, Masuda T, Honda S, Kinoshita M, Harada S, et al. Basic studies on the standardization of patch test. 1970;80(5):301\u201314.","journal-title":"Basic studies on the standardization of patch test."},{"issue":"1","key":"692_CR17","first-page":"39","volume":"18","author":"T Inada","year":"2003","unstructured":"Inada T, Beasley CM Jr, Tanaka Y, Walker DJ. Extrapyramidal symptom profiles assessed with the Drug-Induced Extrapyramidal Symptom Scale: comparison with Western scales in the clinical double-blind studies of schizophrenic patients treated with either olanzapine or haloperidol. Int Clin Psychopharmacol. 2003;18(1):39\u201348.","journal-title":"Int Clin Psychopharmacol"},{"issue":"12","key":"692_CR18","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1176\/appi.ajp.2011.10111704","volume":"168","author":"K Posner","year":"2011","unstructured":"Posner K, Brown GK, Stanley B, Brent DA, Yershova KV, Oquendo MA, et al. The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry. 2011;168(12):1266\u201377.","journal-title":"Am J Psychiatry"},{"issue":"4","key":"692_CR19","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/BF02354306","volume":"65","author":"JP Lindenmayer","year":"1994","unstructured":"Lindenmayer JP, Bernstein-Hyman R, Grochowski S. A new five factor model of schizophrenia. Psychiatr Q. 1994;65(4):299\u2013322.","journal-title":"Psychiatr Q"},{"issue":"1","key":"692_CR20","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1017\/S0033291700050182","volume":"13","author":"TP Hogan","year":"1983","unstructured":"Hogan TP, Awad AG, Eastwood R. A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psychol Med. 1983;13(1):177\u201383.","journal-title":"Psychol Med"},{"key":"692_CR21","doi-asserted-by":"crossref","unstructured":"The EuroQOL Groups. EuroQol\u2014a new facility for the measurement of health-related quality of life. Health Policy. 1990;16(3):199\u2013208.","DOI":"10.1016\/0168-8510(90)90421-9"},{"key":"692_CR22","first-page":"47","volume":"64","author":"S Ikeda","year":"2015","unstructured":"Ikeda S, Shiroiwa T, Igarashi A. Developing a Japanese version of the EQ-5D-5L value set. J Nat Inst Pub Health. 2015;64:47\u201355.","journal-title":"J Nat Inst Pub Health."},{"issue":"5","key":"692_CR23","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.euroneuro.2010.02.001","volume":"20","author":"W Gaebel","year":"2010","unstructured":"Gaebel W, Riesbeck M, von Wilmsdorff M, Burns T, Derks EM, Kahn RS, et al. Drug attitude as predictor for effectiveness in first-episode schizophrenia: results of an open randomized trial (EUFEST). Eur Neuropsychopharmacol. 2010;20(5):310\u20136.","journal-title":"Eur Neuropsychopharmacol"},{"key":"692_CR24","first-page":"2105","volume":"13","author":"YT Hirayasu","year":"2010","unstructured":"Hirayasu YT, Iizumi M, Kikuchi H. A long-term study of paliperidone extended-release tablets in patients with schizophrenia. Jpn J Clin Psychopharmacol. 2010;13:2105\u201335.","journal-title":"Jpn J Clin Psychopharmacol."},{"key":"692_CR25","first-page":"1211","volume":"9","author":"Y Hishikawa","year":"2006","unstructured":"Hishikawa Y, Kaneko S, Kondo T, Sakai A, Ueda H, Abe S, Imamura S, Tashiro T. Phase III long-term clinical study of aripiprazole\u2014a multicenter open-study to determine safety and effectiveness in schizophrenic patients (Aomori, Iwate, and Akita regions study group). Jpn J Clin Psychopharmacol. 2006;9:1211\u201335.","journal-title":"Jpn J Clin Psychopharmacol."},{"key":"692_CR26","first-page":"753","volume":"19","author":"T Kinoshita","year":"2016","unstructured":"Kinoshita T, Waku M, Tamura F, Iwama Y. Long-term safety and efficacy of sublingual asenapine for the treatment of schizophrenia: a phase III extension study with follow-up for 52\u00a0weeks (P06125). Jpn J Clin Psychopharmacol. 2016;19:753\u201370.","journal-title":"Jpn J Clin Psychopharmacol."},{"issue":"6","key":"692_CR27","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1111\/pcn.12654","volume":"72","author":"J Ishigooka","year":"2018","unstructured":"Ishigooka J, Iwashita S, Tadori Y. Long-term safety and effectiveness of brexpiprazole in Japanese patients with schizophrenia: a 52-week, open-label study. Psychiatry Clin Neurosci. 2018;72(6):445\u201353.","journal-title":"Psychiatry Clin Neurosci"},{"key":"692_CR28","unstructured":"National Collaborating Centre for Mental Health. National Institute for Health and Clinical Excellence: Guidance. Schizophrenia: core interventions in the treatment and management of schizophrenia in primary and secondary care (update). Leicester: British Psychological Society. 2009."},{"issue":"11","key":"692_CR29","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1001\/archpsyc.1991.01810350018003","volume":"48","author":"WS Fenton","year":"1991","unstructured":"Fenton WS, McGlashan TH. Natural history of schizophrenia subtypes. II. Positive and negative symptoms and long-term course. Arch Gen Psychiatry. 1991;48(11):978\u201386.","journal-title":"Arch Gen Psychiatry"},{"key":"692_CR30","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.2147\/NDT.S201726","volume":"15","author":"G Cerveri","year":"2019","unstructured":"Cerveri G, Gesi C, Mencacci C. Pharmacological treatment of negative symptoms in schizophrenia: update and proposal of a clinical algorithm. Neuropsychiatr Dis Treat. 2019;15:1525\u201335.","journal-title":"Neuropsychiatr Dis Treat."},{"issue":"8","key":"692_CR31","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1176\/appi.ps.55.8.886","volume":"55","author":"PJ Weiden","year":"2004","unstructured":"Weiden PJ, Kozma C, Grogg A, Locklear J. Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia. Psychiatr Serv. 2004;55(8):886\u201391.","journal-title":"Psychiatr Serv"},{"issue":"2","key":"692_CR32","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/S0896-6273(00)00111-2","volume":"28","author":"DA Lewis","year":"2000","unstructured":"Lewis DA, Lieberman JA. Catching up on schizophrenia: natural history and neurobiology. Neuron. 2000;28(2):325\u201334.","journal-title":"Neuron"},{"issue":"7","key":"692_CR33","doi-asserted-by":"publisher","first-page":"992","DOI":"10.4088\/JCP.v68n0703","volume":"68","author":"J Hamann","year":"2007","unstructured":"Hamann J, Cohen R, Leucht S, Busch R, Kissling W. Shared decision making and long-term outcome in schizophrenia treatment. J Clin Psychiatry. 2007;68(7):992\u20137.","journal-title":"J Clin Psychiatry"},{"issue":"10","key":"692_CR34","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/j.euroneuro.2012.02.008","volume":"22","author":"RE Nielsen","year":"2012","unstructured":"Nielsen RE, Lindstrom E, Nielsen J, Levander S. DAI-10 is as good as DAI-30 in schizophrenia. Eur Neuropsychopharmacol. 2012;22(10):747\u201350.","journal-title":"Eur Neuropsychopharmacol"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-019-00692-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40263-019-00692-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-019-00692-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,26]],"date-time":"2020-12-26T00:30:02Z","timestamp":1608942602000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40263-019-00692-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,27]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["692"],"URL":"https:\/\/doi.org\/10.1007\/s40263-019-00692-6","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,27]]},"assertion":[{"value":"27 December 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The study protocol was approved by the institutional review boards of all participating institutions. This study was also conducted in compliance with the ethical principles stated in the Declaration of Helsinki and with the Good Clinical Practice (GCP) guidelines and other relevant Japanese regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Written informed consent was obtained from all patients or legal guardians (if the patient was\u2009<\u200920\u00a0years old or was hospitalized for medical care and protection) prior to the study based on institutional guidelines.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"This study was funded by Sumitomo Dainippon Pharma Co., Ltd. The open access fee was also paid by Sumitomo Dainippon Pharma Co., Ltd.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"NI reports personal fees from Otsuka, Sumitomo Dainippon, Janssen, Eli-Lilly, and Pfizer and grants from Otsuka and Daiichi-Sankyo outside the submitted work. JI reports grants from Sumitomo Dainippon during the conduct of the study and personal fees from Meiji Seika Pharma, MSD, Astellas, Novartis, Pfizer, Otsuka, Eli Lilly, Takeda, and Eisai outside the submitted work. TH reports personal fees from Meiji Seika Pharma, MSD, Allergan, Eisai, Pfizer, Janssen, Lundbeck, Shionogi, Yoshitomi, Kyowa Hakko Kirin, Mochida, Otsuka, Sumitomo Dainippon, Mitsubishi Tanabe, Eli Lilly, and Takeda outside the submitted work. IN, MM, YK, and HN are employees of Sumitomo Dainippon Pharma Co., Ltd.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}